noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Nielsen Holdings Ltd.

Nielsen helps New Zealand brands expand internationally with greater[...]
Arizona Department of Transportation

ADOT urges motorists to stay alert during Work Zone Awareness Week
GE Vernova Inc.

GE Vernova Foundation Announces Bold, Future-Focused Engineers of[...]

Healthcare

Pappas Capital LLC

07/15/2020 | Press release | Archived content

BioAtla Raises $72.5 Million In Series D Financing

News | 07. 15. 2020

BioAtla

SAN DIEGO, July 15, 2020 -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced closing of a Series D financing round raising $72.5 million. The financing was led by Soleus Capital and joined by several new investors including HBM Healthcare Investments as co-lead, Cormorant Asset Management, Farallon Capital, Pappas Capital, funds managed by Janus Henderson, Boxer Capital, and one other institutional investor. Current investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), also participated in the financing.

Pappas Capital LLC published this content on July 15, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format